USFDA Clearance For Pre Approval Inspection At Ahmedabad Site

21 Apr 2026 CW Team

The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI.

The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting.

Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

"Join industry leaders at RAHSTA Expo, India's premier platform for roads, highways and traffic infrastructure. Register now to explore innovations, network with experts and shape the future of mobility."

The company has received the Establishment Inspection Report and an approval letter from the United States Food and Drug Administration (USFDA) following a Pre-Approval Inspection at its special economic zone (SEZ) oncology injectable manufacturing facility in SEZ1, Ahmedabad. The clearance relates to a new isolator injectable line and was disclosed in a filing dated 16 April, 2026. The inspection took place from fourth to 13th November, 2025 and resulted in documentation that the company said it had received. The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI. The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting. Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

Real Estate

07 Jul 2026

Pecan Realty Completes Rs 1.5 Billion Transactions

Pecan Realty has recently completed four institutional transactions worth over Rs 1.5 billion over the past two years, strengthening its position as an execution-led real estate platform. The deals include resolution-led acquisitions, structured finance transactions and capital partnerships across its development portfolio.The transactions covered acquisitions through the National Company Law Tribunal process and helped provide repayment or exits to both private and public sector lenders. The company said the deals demonstrate its ability to resolve complex project situations, work with instit..

Real Estate

07 Jul 2026

SNN Estates Expands North Bengaluru Housing Project

SNN Estates has announced an expansion of its SNN Estates Felicity residential project in North Bengaluru following strong buyer demand, with 75 per cent of the first-phase inventory sold within three days of launch.The developer will add 76 apartments in the new phase, taking the project's estimated revenue potential to around Rs 1,000 crore upon completion of Phase 2.Spread across 6.5 acres in Rachenahalli, near Manyata Tech Park, the project comprises 604 apartments in 1.5, 2, 2.5, 3 and 4 BHK configurations. The development includes a 50,000-sq-ft clubhouse with amenities such as sports co..

Infrastructure Urban

07 Jul 2026

SCG Drives ASEAN Industrial Transformation Strategy

SCG is strengthening its focus on ASEAN as a key growth region by advancing industrial transformation, enhancing competitiveness and building resilient regional value chains. Thammasak Sethaudom, President and Chief Executive Officer, SCG, highlighted the need for industries to continuously develop capabilities, strengthen resilience and deepen regional cooperation to achieve sustainable long-term growth.SCG views ASEAN as an important growth engine alongside China, supported by favourable demographics, trade connectivity and investment flows. With ASEAN’s GDP projected to grow by around 4.7..